Prevalence, risk factors and associations of primary Raynaud’s phenomenon: systematic review and meta-analysis of observational studies

Rozeena Garner, Rakesh Kumari, Peter Lanyon, Michael Doherty, Weiya Zhang

ABSTRACT

Objective: To systematically review the literature with regard to the prevalence, incidence, risk factors and associations of primary Raynaud’s phenomenon (PRP). 

Method: A systematic review of the literature of observational studies for PRP was undertaken using five electronic databases. Any studies reporting prevalence, incidence and risk factors of PRP were collected. Relative risk or OR and 95% CI were extracted or calculated to present the association between risk factors and PRP. Random effects model was used to pool the results.

Results: 33 articles assessing a total of 33,733 participants were included in this analysis (2 cohort, 17 cross-sectional and 14 case–control studies). The pooled prevalence of PRP was 4.95% (95% CI 2.08% to 8.71%) in the general population. The pooled annual incidence of PRP was 0.25% (95% CI 0.19% to 0.32%). Risk factors and associations for PRP included female gender (OR=1.65, 95% CI 1.42 to 1.91), family history (OR=16.6, 95% CI 7.44 to 36.8), smoking (OR=1.27, 95% CI 1.06 to 1.53), manual occupation (OR=2.66 95% CI 1.73 to 4.08), migraine (OR=4.02, 95% CI 2.62 to 6.17), cardiovascular disease (OR=1.69, 95% CI 1.29 to 2.20) and marital status (married, OR=0.60, 95% CI 0.43 to 0.83). The definition of PRP varied considerably between studies.

Conclusions: This is the first systematic review of the prevalence, incidence, risk factors and associations of PRP. Further study using uniform strict criteria for the condition is required to confirm these findings, particularly the possible association with cardiovascular disease.

INTRODUCTION

In the 19th century, Maurice Raynaud first described Raynaud’s phenomenon (RP) as an episodic, symmetrical, vasospastic disorder resulting in classic triphasic colour change, trophic changes limited to the skin and uncomfortable sensory symptoms of the extremities in the absence of arterial occlusion. Further criteria have been suggested to distinguish primary RP (PRP) from secondary RP, which include detail regarding symptom duration, negative autoimmune serology, normal serum inflammatory markers and capillaroscopy and the clinical absence of any underlying disease. Use of colour charts to aid diagnosis has also been used. Despite this, there is no unifying definition that is used worldwide for PRP.

There have been a number of studies performed in various countries reporting the prevalence of RP. The reported prevalence ranges from less than 1% (in men) and up to 20% (in women) depending on definitions and population selected. In contrast, few studies have examined the incidence of PRP, and the true burden of PRP in the general population remains unclear. PRP is thought to be more common in women, particularly when it develops at a young age. There are also reports of a hereditary component and links with other vasospastic conditions such as migraine.
The primary objective of this study was to perform a systematic review of observational studies to summarise the literature with regard to the prevalence, incidence and risk factors/associations of PRP. The secondary objective was to examine the current definitions used to define PRP worldwide.

**METHODS**

**Literature search—data sources and search strategy**

A comprehensive systematic literature search was undertaken in June 2011 and rerun in October 2014 using five databases: MEDLINE, EMBASE, CINAHL, AMED and PubMed. The search terms for “Raynauds” or “Raynauds disease” were combined with the terms “epidemiology”, “prevalence”, “risk” or “incidence” to generate the citations (see online supplementary appendix 1 for full details of search strategy). “Cross sectional”, “case-control” or “cohort” studies and “systematic review” were also applied for types of studies.

Abstracts were reviewed and the full papers were sought where abstracts were felt to be relevant. Any duplicate articles were excluded (figure 1 and appendix 1 and 2). Where there was difficulty in article retrieval, the authors were contacted via email. The literature search and abstract review was completed by RG and validated by WZ. Reference lists of the review articles were also examined for relevant studies.

**Inclusion and exclusion criteria**

Inclusion criteria: studies reporting the prevalence and/or incidence of PRP; studies reporting potential risk factors associated with PRP; studies reporting human data on PRP in people of any age; studies in any language (4 articles required translation—1 Japanese, 1 Turkish, 1 French, 1 Italian).

Exclusion criteria (figure 1): studies assessing treatment of PRP; studies involving participants with RP secondary to other diseases; studies assessing RP in a specific occupation, for example, people using vibration tools; unpublished material, case reports, editorials, letters or reviews.

**Data extraction and quality assessment**

Study characteristics including age range, gender ratio and total number of participants in the study were documented. The study design, country, setting (ie, hospital...
or community based) were also assessed and noted. If more than one article used the same study population, the article where the data were felt to be presented most clearly was used in the study. The definition of PRP and instruments used to confirm the condition were also documented. The number of cases of PRP out of the number of people studied in a certain time in the general population was documented as unadjusted crude prevalence. Incidence figures were documented if the number of new cases of PRP in the population at risk studied over a given period of time was stated.

Individual OR, relative risk (RR) or HR and their 95% CI were extracted or calculated for the following:
- Constitutional: age, gender
- Environmental: employment, education, marital status and sex hormone medications
- Genetic: family history in 1st degree relatives
- Associations: smoking, alcohol, cardiovascular disease (CVD) and migraine

All studies were reviewed by RG to assess study quality and for data extraction and were validated by WZ. An independent reviewer (RK) assessed a random selection of articles to ensure quality of data extraction. Study quality was assessed according to study design (cohort, cross-sectional and case–control), setting (community or hospital), sample size, case definition, exposure definition, confounding factors and adjustment. Quality scoring for studies was not performed as it is not possible or fair to assign equal weight to different quality aspects related to the study. However, current consensus standards of reporting meta-analysis of observational studies in epidemiology were followed, and subgroup/sensitivity analysis was undertaken to examine the changes of the estimate according to different quality aspects.

Statistical analysis

Individual data for prevalence and incidence were derived from the original report either directly or indirectly from the information provided in each study. The pooled proportion was calculated as the back transform of the weighted mean of the transformed proportion, using inverse arcsine variance weights for the weighted mean of the transformed proportion, pooled proportion was calculated as the back transform of the information provided in each study. The Statistical analysis was undertaken to examine the changes of the estimate according to different quality aspects.

RESULTS

Study characteristics

In total, 2378 citations were found in the initial literature search. All 467 duplicates were removed and 1878 citations were excluded as they did not meet the inclusion criteria (figure 1). The final number of studies available for analysis was 33 (33 733 participants). There were two cohort studies (1 632 participants), 17 cross-sectional studies (25 797 participants) and 14 case–control studies (6 304 participants; table 1). Data for incidence and prevalence were taken from cohort and cross-sectional studies, respectively. Data for risk factors were taken from all studies as long as the results were reported.

Age ranges across different study designs were as follows: case–control (16–79 years), cohort (18–81 years), cross-sectional (12–84 years). Sixty-seven per cent of the studies involved participants recruited in a community-based setting. The majority of studies were conducted in Europe (18)7 18 22 24 26 27 29 30 32 35 37 39 41 45 46 or the USA (10), however, other countries of origin included Japan (2),25 28 New Zealand (1)33 and Israel (1). One comparison study included participants from the USA and France.

Participants were surveyed by means of phone, face-to-face interview and/or postal questionnaire. Twenty-six studies included a physical examination that also included blood testing (including serology), nailfold capillaroscopy and use of colour chart/photographs (table 1).

Ten studies used specific criteria to define PRP. (3 studies) Allen and Brown; LeRoy and Medsger2; UK Scleroderma Study Group4. The remaining studies used a combination of cold sensitivity, varying degrees of colour change and sensory symptoms via questionnaire or interview to define PRP. Colour charts or photographs to indicate colour change were used in 12 studies (6 24 30 33 36 37 39 41–43). In 15 studies, blood testing including serology and/or inflammatory markers was performed.6 8 9 11 12 24 30 33 36 37 39–44

Studies with clear definition of PRP or clear exclusion criteria for secondary RP were categorised as ‘definite PRP’ in this study. Studies with less clear definition of PRP were categorised as ‘possible PRP’. Studies with clear definition of secondary RP were excluded.

Prevalence of PRP

The overall prevalence for definite PRP varied from 1.6% to 7.2% in six cross-sectional studies in the general population sample: women: 2.1–15.8% and men: 0.8–6.5% (5 21 23 27 29 33). The pooled prevalence was 4.85% (95% CI 2.08% to 9.75%) in women and 4.12% (95% CI 1.60% to 7.74%) in men. We used the Harbord test to detect publication bias (1.59, 95% CI –21.6 to 24.8; p=0.87). The overall prevalence for possible PRP ranges from 3.98% to 12.7% (women: 4.5–17.9% and men: 3.4–7.2%) in three cross-sectional...
The prevalence in specific populations varies depending on the studies (Table 2).

In six studies assessing the general population we found the lowest prevalence of PRP in Japan, with an overall prevalence of 1.6 (2.1% in women, 1.1% in men).25 Highest overall prevalence figures were found in the USA with a median prevalence of 7.5% (7.8% in women, 5.8% in men).21 23 A study from France also showed high prevalence figures of 11.75% in women and 6.3% in men (median values;31 Table 3).

Table 1 Characteristics of studies

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cohort</th>
<th>Cross-sectional</th>
<th>Case–control</th>
<th>All studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of studies</td>
<td>2</td>
<td>17</td>
<td>14</td>
<td>33</td>
</tr>
<tr>
<td>Number of participants</td>
<td>1632</td>
<td>25 797</td>
<td>6304</td>
<td>33 733</td>
</tr>
<tr>
<td>Age</td>
<td>18–81</td>
<td>12–84</td>
<td>16–79</td>
<td>12–84</td>
</tr>
<tr>
<td>Setting</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Community based</td>
<td>2</td>
<td>14</td>
<td>5</td>
<td>21</td>
</tr>
<tr>
<td>Hospital based</td>
<td>0</td>
<td>2</td>
<td>9</td>
<td>11</td>
</tr>
<tr>
<td>Community and hospital</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Region of study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td>1</td>
<td>2</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>Europe</td>
<td>1</td>
<td>11</td>
<td>6</td>
<td>18</td>
</tr>
<tr>
<td>France and USA</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Japan</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>New Zealand</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Israel</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Questionnaire</td>
<td>0</td>
<td>5</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Questionnaire+examination</td>
<td>2</td>
<td>9</td>
<td>12</td>
<td>23</td>
</tr>
</tbody>
</table>

*Diagnosis was classified as questionnaire based or questionnaire and examination based. The former includes phone survey, postal questionnaire and face-to-face interview whereas the latter includes clinical examination, blood testing including serology, use of colour chart/photographs and capillaroscopy in addition to the questionnaire. Colour chart/photographs were used in 12 studies (cohort 2, cross-sectional 7, case–control 3) and capillaroscopy was used in 10 studies (cohort 1, cross-sectional 2, case–control 7).

Five studies reported prevalence of PRP by age.28–30 34 Three did not find any age-related prevalence.28 30 Purdie et al34 reported a higher prevalence of PRP in younger compared to older age groups, whereas Fraenkel et al38 reported higher prevalence in older age groups in men (adjusted OR=2.3, 95% CI 1.0 to 5.2 highest vs lowest tertile) but not in women (adjusted OR=0.9, 95% CI 0.4 to 1.6). Jones et al39 also showed a slight increase in prevalence by age in yearly increments between ages 12 and 15 years.
Incidence of primary Raynaud's phenomenon

Only two studies reported incidence rates. Carpentier et al reported an annual incidence rate of 0.25% (95% CI 0.17% to 0.33%), with 0.24% in women and 0.26% in men and Suter et al reported a 7-year incidence of 1.87% (2.2% in women and 1.5% in men), which was converted to an annual incidence rate of 0.26% (95% CI 0.17% to 0.39%). The pooled annual incidence rate of these two studies was therefore 0.25% (95% CI 0.19% to 0.32%).

Risk factors and associations

In 18 studies (23 197 participants), there was a positive association between female gender and PRP (OR=1.65, 95% CI 1.42 to 1.91). Family history, assessed in two studies looking at first-degree relatives, also had a positive significant association with PRP (OR=16.6, 95% CI 7.44 to 36.8). No significant association was found with education beyond primary school age (table 4). Manual occupation (not including vibration

### Table 2 Prevalence of primary Raynaud’s phenomenon in 17 studies

<table>
<thead>
<tr>
<th>First author</th>
<th>Country Setting</th>
<th>Sample size</th>
<th>Age mean (SD/range)</th>
<th>Female (%)</th>
<th>Overall (%)</th>
<th>Female (%)</th>
<th>Male (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand (1997)</td>
<td>Boston, USA Com</td>
<td>4182</td>
<td>51.8</td>
<td>52.2</td>
<td>7.2</td>
<td>7.8</td>
<td>6.5</td>
</tr>
<tr>
<td>Fraenkel (1999)</td>
<td>Boston, USA Com</td>
<td>1525</td>
<td>53.9</td>
<td>52.5</td>
<td>7.8</td>
<td>9.6</td>
<td>5.8</td>
</tr>
<tr>
<td>Harada (1991)</td>
<td>Ehime, Japan Hosp</td>
<td>3873</td>
<td>20–70</td>
<td>51.6</td>
<td>1.6</td>
<td>2.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Ivorra (2001)</td>
<td>Valencia, Spain Com</td>
<td>276</td>
<td>54.4</td>
<td>74.3</td>
<td>3.3</td>
<td>3.4</td>
<td>2.8</td>
</tr>
<tr>
<td>Maricq (1997)*</td>
<td>South Carolina, USA Com</td>
<td>2086/432</td>
<td>18+ NS</td>
<td>NS NS</td>
<td>3.4</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Toulon, France</td>
<td>1998/189 Com</td>
<td>18+ NS</td>
<td>NS NS</td>
<td>11.4</td>
<td>2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nyons, France</td>
<td>1996/345 Com</td>
<td>18+ NS</td>
<td>NS NS</td>
<td>5.8</td>
<td>6.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grenoble, France</td>
<td>2009/272 Com</td>
<td>18+ NS</td>
<td>NS NS</td>
<td>12.1</td>
<td>6.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tarentaise, France</td>
<td>2000/296 Com</td>
<td>18+ NS</td>
<td>NS NS</td>
<td>15.8</td>
<td>6.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onbasi (2005)</td>
<td>Van, Turkey Com</td>
<td>768</td>
<td>29.2 (10.4)</td>
<td>46.6</td>
<td>5.9</td>
<td>7.0</td>
<td>4.9</td>
</tr>
</tbody>
</table>

### Table 3 Prevalence of primary Raynaud’s phenomenon in general population studies

| Prevalence of definite primary Raynaud’s phenomenon in general population studies
<table>
<thead>
<tr>
<th>First author</th>
<th>Country Setting</th>
<th>Sample size</th>
<th>Age mean (SD/range)</th>
<th>Female (%)</th>
<th>Overall (%)</th>
<th>Female (%)</th>
<th>Male (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand (1997)</td>
<td>Boston, USA Com</td>
<td>4182</td>
<td>51.8</td>
<td>52.2</td>
<td>7.2</td>
<td>7.8</td>
<td>6.5</td>
</tr>
<tr>
<td>Fraenkel (1999)</td>
<td>Boston, USA Com</td>
<td>1525</td>
<td>53.9</td>
<td>52.5</td>
<td>7.8</td>
<td>9.6</td>
<td>5.8</td>
</tr>
<tr>
<td>Harada (1991)</td>
<td>Ehime, Japan Hosp</td>
<td>3873</td>
<td>20–70</td>
<td>51.6</td>
<td>1.6</td>
<td>2.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Ivorra (2001)</td>
<td>Valencia, Spain Com</td>
<td>276</td>
<td>54.4</td>
<td>74.3</td>
<td>3.3</td>
<td>3.4</td>
<td>2.8</td>
</tr>
<tr>
<td>Maricq (1997)*</td>
<td>South Carolina, USA Com</td>
<td>2086/432</td>
<td>18+ NS</td>
<td>NS NS</td>
<td>3.4</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Toulon, France</td>
<td>1998/189 Com</td>
<td>18+ NS</td>
<td>NS NS</td>
<td>11.4</td>
<td>2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nyons, France</td>
<td>1996/345 Com</td>
<td>18+ NS</td>
<td>NS NS</td>
<td>5.8</td>
<td>6.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grenoble, France</td>
<td>2009/272 Com</td>
<td>18+ NS</td>
<td>NS NS</td>
<td>12.1</td>
<td>6.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tarentaise, France</td>
<td>2000/296 Com</td>
<td>18+ NS</td>
<td>NS NS</td>
<td>15.8</td>
<td>6.3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 4 Regional variation of prevalence of primary Raynaud’s phenomenon for general population studies including prevalence rates for males and females

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of studies</th>
<th>Number of participants</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Male</td>
</tr>
<tr>
<td>USA*</td>
<td>3</td>
<td>6 139</td>
<td>5.8</td>
</tr>
<tr>
<td>France*</td>
<td>1</td>
<td>1 102</td>
<td>6.3</td>
</tr>
<tr>
<td>Spain</td>
<td>1</td>
<td>276</td>
<td>2.8</td>
</tr>
<tr>
<td>Turkey</td>
<td>1</td>
<td>768</td>
<td>4.9</td>
</tr>
<tr>
<td>Japan</td>
<td>1</td>
<td>3 873</td>
<td>1.1</td>
</tr>
<tr>
<td>Total</td>
<td>6</td>
<td>12 158</td>
<td></td>
</tr>
</tbody>
</table>

*Median values calculated for prevalence. The US gender figures include data from Maricq et al (France and the USA). Total US prevalence figure includes data from two US-only studies.
tool use) had an OR of 2.66 (95% CI 1.73 to 4.08) in one study of 3873 participants. In four studies, being married was associated with a lower risk of PRP with OR of 0.60 (95% CI 0.43 to 0.83) compared with being single/divorced/widowed. Smoking was found to have an association in nine studies giving a pooled OR of 1.27 (95% CI 1.06 to 1.53). A study by Smyth et al. reported a positive association of CVD with PRP with an OR of 1.69 (95% CI 1.22 to 2.34). Cardiovascular disease includes history of angina, myocardial infarction, coronary insufficiency, intermittent claudication, congestive cardiac failure, stroke and transient ischaemic attack. Hypercholesterolaemia and hypertension did not show a positive association in combined oestrogen and progesterone replacement therapy alone in two studies with OR of 2.34 (95% CI 1.42 to 3.84). However, no significant association was found in combined oestrogen and progesterone replacement therapy in postmenopausal women or in contraceptive pill (CP) use in two other studies. A study by Smyth et al. looking at allele frequencies of known polymorphisms of candidate vasoactive mediator genes (eNOS, BKRG, ET01 and ETA receptor genes) did not show any association. Shemirani et al. looked at clotting factors in participants with PRP and found a significant association with methylenetetrahydrofolate reductase C677T mutations (OR=0.4, 95% CI 0.2 to 0.9) but no difference in other thrombosis-associated alleles (FVLedien, prothrombin G20210 A).

**Discussion**

This is the first meta-analysis of the literature for the prevalence, incidence, risk factors and associations of PRP. Overall, the pooled mean prevalence of PRP in the general population was 4.85% (95% CI 2.08% to 8.71%; figure 2) and the mean incidence was 0.25% (95% CI 0.17% to 0.33%) per annum. Major risk factors/associations of PRP include female gender, family history of PRP, migraine, smoking, CVD, manual occupation, oestrogen replacement therapy and possibly, marital status (table 4).

Varying in prevalence were observed between countries (table 3), though this could reflect use of different diagnostic criteria rather than real differences in prevalence. The heterogeneity of prevalence figures may also reflect the differences in the way the studies were conducted, the selection of participants (eg, age and gender) and the disease definition. All studies (except for Maricq et al.) demonstrate a higher prevalence of...
PRP in women. This may be due to a relationship with female hormones as two studies found an association between PRP and use of oestrogen replacement therapy alone.23–38 although no association was found between combined oestrogen and progesterone replacement and the CP.10–11 38 In contrast, prevalence of PRP does not increase with age in five published studies with a wide age range of participants from 12 up to 84 years.6 28–30 34 This accords with the clinical observation that PRP usually starts in teenage years and that later development, which is far less common, is characteristic of secondary RP. While the former may be driven predominantly by genetic risk factors, later onset ‘primary’ Raynaud’s may be predominantly influenced by environmental exposures such as vascular microtrauma from manual usage and vibrating tools. In terms of other environmental factors we did find a weak negative association between marital status and PRP with an OR of 0.60 (95% CI 0.43 to 0.83) in those that are married versus single/separated/widowed/divorced.6 28–30 34 This accords with the clinical observation that PRP usually starts in teenage years and that later development, which is far less common, is characteristic of secondary RP.

The association of CVD and autoimmune disease is well documented and thought to be due to accelerated atherosclerosis as a result of chronic inflammation, treatment such as glucocorticoids as well as the traditional risk factors for CVD.46–52 A link between CVD and PRP has been shown in only one study44 and the reason for this association is not known. It is unlikely to be due to an inflammatory process or related to medication, and with PRP having predominance for the female population and onset at a young age, it is not clear if traditional cardiovascular risk factors play a part. However, smoking was found to have a positive association with PRP in our study (OR=1.27, 95% CI 1.06 to 1.53). It is well known that smoking is one of the three (smoking, hypertension and hyperlipidaemia) main risk factors for cardiovascular and cerebrovascular disease.53–56 Smoking may have the same risk factor for PRP and CVD. Whether smoking causes PRP first and then CVD is an interesting question that deserves further research. More interestingly, we found a very strong association between migraine and PRP (OR=4.02, 95% CI 2.62 to 6.17). It has been previously shown that migraine is due to a cascade of vascular and neural events.46 47 However, a review by Rosamund suggested that migraine was not shown to be linked with coronary heart disease but possibly shares a common underlying pathophysiology with RA and other vasospastic disorders such as variant angina.60 61 It is thought there may be other factors that could affect the underlying mecanism for these vasospastic conditions as episodes occur at different times with differing precipitants.62 63 Further study may help clarify whether PRP is a benign vasospastic disorder or whether there is underlying pathology affecting the vascular wall associated with traditional risk factors seen in CVD.

There are a number of caveats to this study. Firstly, it was striking that there was no uniform definition for diagnosis of PRP. Only 39% of studies looking at prevalence had a precise definition for PRP, thereby reducing the number of studies we used to assess pooled prevalence. It is possible that the variation in definition of PRP together with the way participants were recruited and assessed may have led to underestimation or overestimation of the true prevalence of PRP in the general population. We feel that an amalgamation of the generally more commonly used definitions would ensure that the diagnosis is clear by assessing symptoms, using a colour chart or photographs for confirmation of colour change and carefully exclude underlying conditions including checking for digital infarcts/ulceration, nailfold capillaroscopy, and assessing autoimmune screen and inflammatory markers. Secondly, as our objective was to specifically examine the epidemiology of PRP, a large proportion of studies were excluded because they focused on secondary Raynaud’s phenomenon, especially related to connective tissue diseases and vibration white finger. In addition, we also excluded studies that looked at investigation or treatment of PRP. This left only a small number of studies to assess. From the studies included, there was a great deal of variation in the population of participants used. Nine of the 17 studies used investigated participants in the general population, whereas the remainder examined specific populations such as single gender, children or hospital/medical personnel. Furthermore, there was considerable variation in the risk factors addressed in each study and this may have affected the significance and association, or lack of association between the risk factors and PRP. We tried to extract as many risk factors from each study as possible to use in our analysis. In the future, a larger multinational population study may help us to get a better understanding of the disease. This would be particularly useful if standardised criteria were used to include participants in the studies, using strict definition for PRP (as mentioned previously), and data were collected in a similar fashion assessing a wide variety of possible risk factors (particularly related to CVD and vasospastic disorders) for more accurate data analysis.

CONCLUSION

This first systematic review summarises the burden of PRP in the general population using published literature. It is not a rare condition (prevalence 4.85% and annual incidence 0.25%). It starts at a young age, is more common in women, and associates with a family history and with smoking. In addition, people with PRP are four times more likely to have migraine than those without this condition.

Acknowledgements The authors sincerely thank Joanna Ramowski and Helen Richardson for article retrieval and support. They specially thank Anu Suokas, Karin Tatsumo, Professor Tiraje Truncer, Ana Valdes and Maggie Wheeler for language translation.
Contributors WZ, MD, PL and RG were involved in study conception and design. RG, RK and WZ were involved in acquisition of the data. RG and WZ were involved in statistical analysis. RG, WZ, MD and PL were involved in analysis and interpretation of the data. RG, WZ, MD and PL were responsible for manuscript preparation and final approval of the manuscript.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

49. Peters M, Symmons D, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients...


Prevalence, risk factors and associations of primary Raynaud’s phenomenon: systematic review and meta-analysis of observational studies

Rozeena Garner, Rakesh Kumari, Peter Lanyon, Michael Doherty and Weiya Zhang

*BMJ Open* 2015 5:
doi: 10.1136/bmjopen-2014-006389

Updated information and services can be found at:
http://bmjopen.bmj.com/content/5/3/e006389

These include:

**Supplementary Material**
Supplementary material can be found at:
http://bmjopen.bmj.com/content/suppl/2015/03/16/bmjopen-2014-006389.DC1

**References**
This article cites 62 articles, 14 of which you can access for free at:
http://bmjopen.bmj.com/content/5/3/e006389#BIBL

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Epidemiology (1982)
- Rheumatology (148)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/